Similar articles

• Issues of bioequivalence and cost equivalence.

  Al-Inany HG. Al-Inany HG. Fertil Steril. 2002 Aug;78(2):438; author reply 438-9. doi: 10.1016/s0015-0282(02)03258-2. Fertil Steril. 2002. PMID: 12137895 No abstract available.
• Models of cost-effectiveness of recombinant FSH versus urinary FSH.

  Al-Inany H, Afnan M. Al-Inany H, et al. Hum Reprod. 2002 Jun;17(6):1671-3; author reply 1673-4. doi: 10.1093/humrep/17.6.1671-b. Hum Reprod. 2002. PMID: 12042297 No abstract available.
• Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective.

  Balasch J, Barri PN. Balasch J, et al. J Assist Reprod Genet. 2001 Feb;18(2):45-55. doi: 10.1023/a:1026501821849. J Assist Reprod Genet. 2001. PMID: 11285980 Free PMC article.
• The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature.

  Šprem Goldštajn M, Mikuš M, Ćorić M, Orešković S, Dumančić S, Noventa M, Buzzaccarini G, Andrisani A, Laganà AS. Šprem Goldštajn M, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):553-558. doi: 10.1080/14737167.2021.1910026. Epub 2021 Mar 31. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33784935 Review.
• What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone.

  Bergh C. Bergh C. Hum Reprod. 1999 Jun;14(6):1418-20. doi: 10.1093/humrep/14.6.1418. Hum Reprod. 1999. PMID: 10357950 Review. No abstract available.